Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship.

Dorotheé Kasteleijn-Nolst TrenitéChristian BrandtThomas MayerFelix RosenowBernd SchmidtBernhard J SteinhoffAnne GardinGeorges ImbertDonald JohnsAlexandros SagkriotisKlaus Kucher

Published in: Epilepsia (2015)

The dose-dependent positive effect of BGG492 on the PPR and SPR in patients with photosensitive epilepsy in this proof-of-concept study supports further investigation of AMPA receptor antagonists in large-scale phase III trials.

Keyphrases

phase iii
open label
clinical trial
endothelial cells
phase ii
double blind
induced pluripotent stem cells
randomized controlled trial